Emerging Treatment Options for Familial Hypercholesterolemia

Title:

Emerging Treatment Options for Familial Hypercholesterolemia

Topic: Cardiology
Relevant Terms: Dyslipidemia
Primary Audience: General Cardiologists, Atherosclerosis Specialists, Interventional Cardiologists, Preventive Cardiologists, Diabetologists, Lipid and Metabolism Specialists
Launch Date: 11-Jun-15
Credits: AMA PRA Category 1 Credit
1 ANCC contact hour
1 AANP contact hour of continuing education
Expiration Date: The accreditation for this activity has expired.
Curriculum Name: Cardiovascular Risk in Patients with Primary Hyperlipidemia and Familial Hypercholesterolemia...

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Review the underlying genetic mutations and the role of genetic screening for heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH) as it relates to diagnosis and treatment of familial hypercholesterolemia and in response to statins, ezetimibe and proprotein convertase subtilisin kexin 9 (PCSK9) monoclonal antibody treatment
  2. Discuss the emerging evidence on genetic mutations and their potential therapeutic significance in the development of novel low-density lipoprotein cholesterol (LDL-C) targets
  3. Identify the relationship of LDL-C reduction and cardiovascular disease (CVD) risk reduction including the risk in HeFH and HoFH
  4. Discuss the clinical presentation and implications of HeFH and the use of optimal LDL-C target goals for these patients based on current consensus recommendations 

    Faculty

    Evan Stein, MD, PhD
    Director Emeritus
    Metabolic & Atherosclerosis Research Center
    Cincinnati, OH
    Michael H. Davidson, MD
    Clinical Professor of Medicine
    Director, Preventive Cardiology
    The University of Chicago
    Pritzker School Of Medicine
    Chicago, IL
    Disclosure of Conflicts Of Interest Policy​
    It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Author Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other author for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review.
     
    Disclaimer
    This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.
     
    Faculty Disclosures
    Evan Stein, MD, PhD discloses the following relevant financial relationships:
    Consultant - Amgen, Inc.; AstraZeneca; Bristol-Myers Squibb Company; Catabasis Pharmaceuticals, Inc.; CymaBay Therapeutics; Gemphire Therapeutics Inc.; Genentech, Inc., a member of the Roche Group; Regeneron Pharmaceuticals, Inc.  
     
    Clinical Investigator - Amgen, Inc.; AstraZeneca; Bristol-Myers Squibb Company; Genentech, Inc., a member of the Roche Group; Regeneron Pharmaceuticals, Inc.; sanofi-aventis U.S. Inc.
     
    Michael H. Davidson, MD discloses the following relevant financial relationships:
    Consultant - Amgen, Inc.; Regeneron Pharmaceuticals, Inc.; sanofi-aventis U.S. Inc.
     
    Accreditor Disclosures
    Dorothy Caputo, MA, BSN, RN- Lead Nurse Planner
    Discloses no financial relationships with pharmaceutical or medical product manufacturers.
     
    Bernadette Marie Makar, MSN, NP-C, APRN-C- Nurse Planner
    Discloses no financial relationships with pharmaceutical or medical product manufacturers.
     
    AKH planners and reviewers have no relevant financial relationships to disclose.
     
    Disclosure of Unlabeled Use​
    This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
     
    Commercial Support
    This activity is supported by an educational grant from Amgen Inc. and sanofi-aventis U.S. Inc.
     
     
     
    CME/CE Credit provided by AKH Inc., Advancing Knowledge in Healthcare

     
     
     
    Physicians
    AKH Inc., Advancing Knowledge in Healthcare is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
     
    AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
     
    Physician Assistants
    NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.
     
    Nursing
    AKH Inc., Advancing Knowledge in Healthcare is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
    This activity is awarded 1.0 contact hour.
     
    Nurse Practitioners
    AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider Number: 030803.
    This program is accredited for 1.0 contact hour, which includes 0.75 hours of pharmacology. 
    Program ID #21510.
     
    This program was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support Standard.
     
    Instructions
    To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. You must participate in the entire activity to receive credit. If you have questions about this CME/CE activity, please contact AKH Inc. at jgoldman@akhcme.com.
     
    Privacy Policy
    http://akhcme.com/privacy
     
     
    COURSE VIEWING REQUIREMENTS
    Supported Browsers:
    Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
    Google Chrome 28.0+ for Windows, Mac OS, or Linux
    Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
    Safari 6+ for Mac OSX 10.7 and above

    For video playback, install the latest version of Flash or Quicktime.